Shockwave Medical (SWAV) Tops Q1 EPS by 24c, Raises FY Guidance

Shockwave Medical (NASDAQ: SWAV) reported Q1 EPS of $1.03, $0.24 better than the analyst estimate of $0.79. Revenue for the quarter came in at $161.1 million versus the consensus estimate of $147.3 million.

GUIDANCE:

Shockwave Medical sees FY2023 revenue of $700-720 million, versus the consensus of $672 million.

• This compares to previous revenue guidance for the full year of 2023 of $660 million to $680 million.

For earnings history and earnings-related data on Shockwave Medical (SWAV) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Investing.com’s stocks of the week